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1. Introduction
　Adenoid cystic carcinoma（AdCC）is one of the most 
common malignant tumors of the salivary glands.  The 
tumor grows slowly, but spreads relentlessly into adja-
cent tissues, so recurrence is common and distant me-
tastasis, especially to the lungs, is very frequent1.  Since 
AdCC is resistant to radiotherapy and chemotherapy, 
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Abstract : Adenoid cystic carcinoma（AdCC）is one of the most common malignant tumors of the salivary 
glands and has unique clinical features and behavior.  AdCC grows slowly, but spreads relentlessly into adja-
cent tissues, with a proclivity for invading nerve and endothelial sheaths.  Moreover, the frequency of recur-
rence and distant metastasis of AdCC is very high.  In vivo and in vitro, AdCC produces a large amount of 
extracellular matrix（ECM）, including basement membrane（BM）components, elastin, and mucopolysac-
charides.  The accumulation of ECM components in intercellular spaces results in the formation of a pseudo-
cyst, which is the characteristic architecture of AdCC.  AdCC cells degrade considerable amounts of mesenchy-
mal-elaborated ECM through the urokinase-type plasminogen activator（uPA）-plasmin system.  By contrast, 
tumor-produced ECM is resistant to degradation, because it contains plasminogen activator inhibitor type 1
（PAI-1）.  The migration response of AdCC cell lines to ECM, especially type I and type IV collagens, is much 
stronger than that of oral squamous cell carcinoma（SCC）cell lines, while both cell types generally show 
similar patterns of integrin subunit expression.  The AdCC cell response to collagens is largely and exclusively 
inhibited by anti-α2 integrin antibody.  Surface uPA receptor（uPAR）expression by AdCC cell lines is greater 
than that by SCC cell lines and increases in response to collagen stimulation.  This is accompanied by the as-
sembly of numerous focal adhesions, consisting of the adapter proteins uPAR,α2 integrin, vinculin, and paxil-
lin.  A role for uPAR in cell migration and assembly of adaptor proteins was also demonstrated by transfecting 
AdCC cells with an antisense uPAR RNA, which strongly reduced both responses.  Therefore, the proclivity of 
AdCC cells to migrate to type I and IV collagens might be due to the overexpression of uPAR, which also plays 
a key role in focal adhesion assembly.  In conclusion, the invasiveness of AdCC cells might be regulated by the 
interaction of uPA-uPAR with integrin.
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effective forms of treatment are required.  Histological-
ly, the tumor is characterized by a cylindrical or cystic 
stroma surrounded by anastomosing cords of epithelial 
tumor cells.  The cystic stroma and the interstitium sur-
rounding the tumor islands are often hyalinized and 
contain various substances, including collagen-like ﬁ -
bers, elastin, basement membrane constituents, and 
mucopolysaccharides1.
　Invasion and metastasis are characteristic features of 
malignant tumors.  Although the molecular mechanisms 
underlying metastasis are complex, it is clear that tu-
mor cells must migrate through the extracellular matrix
（ECM）in order to invade local tissues and metastasize 
to distal sites.  Migrating cells use both adhesion mole-
cules and proteolytic enzymes to regulate their interac-
tion with and response to the ECM, and cooperation be-
tween these components operates at several levels : 
integrin signaling induces proteases2, proteases co-local-
ize with integrins3, and proteases regulate the interface 
between integrins and the cytoskeleton4.  A protease 
system intimately connected to integrins comprises uro-
kinase-type plasminogen activator（uPA）, the uPA re-
ceptor（uPAR）, and plasmin5.
　The plasminogen activation system, which is made up 
of plasminogen activators, their inhibitors, plasmino-
gen, and the respective cell-surface-binding proteins 
and receptors, plays a central role in cell invasion. 
Along with tissue-type plasminogen activator, uPA pro-
motes the formation of plasmin, the key protease in ﬁ -
brinolysis.  Plasmin activates matrix-metalloproteases, 
which constitute a proteolytic system for cell migration 
and tissue remodeling6，7. Together, these proteases fa-
cilitate cell invasion by（1）activating latent growth 
factors or releasing them from their ECM-binding sites, 
and（2）degrading a variety of proteins in the ECM. 
Different plasminogen activator inhibitors（PAIs）neu-
tralize plasminogen activator, primarily fast-acting 
PAI-18.  PAI-1 is a serine protease inhibitor, but, unlike 
other proteases, its active conformation is stabilized by 
high-afﬁ nity binding to ECM-associated vitronectin.  In 
addition to producing uPA, malignant cells also synthe-
size the uPA inhibitor PAI-1, thereby regulating PA ac-
tivity levels in the cellular microenvironment8，9. There-
fore, tumor-cell-mediated proteolysis may be controlled 
by the ﬁ ne regulation of tumor-cell-secreted proteases 
and protease inhibitors.
　uPA binds to a glycosyl phosphatidylinositol（GPI）
-anchored uPAR, which consists of three homologous do-
mains（D1, D2, and D3）.  The binding of proteins such 
as uPA, vitronectin, and PAI-1 to uPAR involves a direct 
interaction with D1, but requires the integrity of the 
full-length receptor7.  uPA bound to uPAR exhibits en-
hanced proteolytic activity and directly activates plas-
minogen and matrix metalloproteases, which, in turn, 
enhance ECM degradation7.  The receptor-binding do-
main of uPA is located in the amino-terminal fragment
（ATF; residues 1-135）of the uPA molecule and does 
not involve the protease domain.  Independent of its 
proteolytic function in matrix degradation, the uPA-
uPAR interaction 1）mediates several signaling events, 
2）regulates cell adhesion on vitronectin-coated surfac-
es, 3）modulates integrin activity, 4）triggers cell mi-
gration, and is strongly correlated with the metastatic 
potential of various tumors10.
　Integrins are ubiquitous, heterodimeric transmem-
brane receptors that anchor the cell to the ECM and the 
cytoskeleton to the plasma membrane11.  Integrin recep-
tors mediate cell adhesion, migration, and bidirectional 
signal transduction via interactions with ECM pro-
teins11，12.  In particular, the ECM-integrin interaction 
leads to the reorganization of the actin cytoskeleton, 
initiates signal transduction cascades, and coordinates 
the response to growth factors12.  Recent work points to 
important interactions between integrins, cytoskeletal 
components, and signaling molecules13.
　Focal adhesions are specialized cell adhesion sites 
that transduce signals from the ECM intracellularly. 
The assembly and disassembly of focal adhesions result 
in the formation and displacement of cellular stress ﬁ -
bers.  On ligand activation, transmembrane ECM recep-
tors, such as integrins, cluster at focal adhesions, which 
are physically connected to the cytoskeleton by stable 
and transient interactions14.  A characteristic property 
of most focal adhesion proteins is their multi-domain 
structure.  For example, vinculin can interact with at 
least ten other focal adhesion proteins, including actin, 
tensin, paxillin, and talin, although probably not simul-
taneously15.  In addition to recruiting non-catalytic com-
ponents, protein kinases also cluster at focal adhesions 
in response to cell adhesion, which leads to increased 
phosphorylation of focal adhesion proteins15.  Paxillin, 
another important multi-domain adaptor protein, func-
tions in recruiting both signaling and structural mole-
cules to focal adhesions16.  The COOH terminus of paxil-
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lin is composed of four Lin 11, Isl 1, Mcc 3（LIM）
domains, which mediate paxillin targeting to focal adhe-
sions17.  The NH2 terminus of paxillin supports the 
binding of vinculin and several protein tyrosine kinases, 
including focal adhesion kinase（FAK）, proline-rich ty-
rosine kinase 2（PYK2）, C-terminal Src kinase（Csk）, 
and Src.  Paxillin leucine-rich sequences（LDXLLXXL）, 
called LD motifs, serve as binding sites for both FAK 
and vinculin17.
　AdCCs are characterized by their relentless spread 
into adjacent tissues, and their high frequency of recur-
rence and distant metastasis.  Tumor invasion is the 
ﬁ rst critical step in a complex process that leads to the 
formation of metastases, and the mechanism behind 
this step is the focus of this review.
2. Salient clinical features related to tumor inva-
sion
　AdCC occurs most often in adults in the ﬁ fth through 
seventh decades of life.  While a female predominance 
for AdCC has been reported in some studies18, others 
did not ﬁ nd gender-speciﬁ c differences in the incidence 
of these tumors16，19.  AdCC occurs predominantly in the 
submandibular, parotid, and minor salivary glands, 
with more than half of the tumors in the latter located 
in the palate.  The tumor is apparent in the major or 
minor salivary glands as a swelling or mass.  It grows 
slowly, but spreads relentlessly into adjacent tissues. 
Invasive AdCC of the parotid gland leads to paralysis of 
the facial nerve, whereas pain and ulceration often de-
velop in tumors of the minor salivary gland.
　It has generally been accepted that surgery is the 
preferred treatment for AdCC, and complete excision at 
initial surgery is associated with a favorable survival 
rate and cure.  Nonetheless, in about 40% of patients 
there is recurrence of the tumor after surgery.  Since 
margin status signiﬁ cantly inﬂ uences local control of 
the tumor and ultimately patient survival, careful his-
tological observation of the surgical margins is essen-
tial.  AdCCs tend to proliferate discontinuously, with 
tiny scattered tumor nests that spread widely and deep-
ly into adjacent tissues35.  Cumulative evidence sug-
gests that microscopic deposits to distant sites occur 
early in the growth of the primary tumor.  Indeed, one 
third to half of AdCC patients develop metastases dur-
ing the follow-up period, even if the primary tumor was 
controlled20.  The most frequent site of metastasis is the 
lung, followed by other organs, such as bone and liver. 
Perineural invasion is one parameter predicting distant 
metastasis1，21.
　Unlike most other types of salivary gland carcinoma, 
in AdCC distant metastasis is far more frequent than 
regional lymph node involvement, and this is why elec-
tive neck dissection is not indicated.  Radiation therapy 
may improve local tumor control, especially when there 
is microscopic residual tumor22-24.  Fast neutron radio-
therapy provides higher local control rates than conven-
tional photon radiation therapy, even for palliation of 
unresectable or recurrent tumor25，26.  While the 5-year 
survival rate of patients with AdCC is relatively favor-
able, because of the invasiveness of the tumor and its 
resistance to conventional radiotherapy and chemother-
apy, the long-term prognosis is extremely poor in most 
patients.  Therefore, the development of effective new 
approaches for treating AdCC is urgently needed.
3. Histological characteristics
　AdCC is composed of distinct populations of cells, 
which can be divided into two types based on ultrastruc-
tural and histochemical studies1，27-29.  Type A cells com-
prise cells of the pseudocyst lining, nonluminal cells, 
and peripheral cells, and exhibit several myoepithelial 
markers.  Type B ductal or luminal cells express several 
secretory markers.  While type A cells are abundant in 
tumor tissue, type B cells are rather scarce.  Immuno-
histochemistry studies have shown that type A cells are 
positive for muscle-speciﬁ c actin, low-molecular-weight 
cytokeratin, and S-100, whereas type B cells express 
carcinoembryonic antigen（CEA）, epithelial membrane 
antigen（EMA）, high-molecular-weight cytokeratin27. 
Co-expression of cytokeratin and vimentin has been ob-
served in tumor cells of a variety of salivary gland neo-
plasms, including AdCC, pleomorphic adenoma, and 
carcinomas in pleomorphic adenoma30，31.  By contrast, 
human normal salivary glands co-express these pro-
teins, but only in areas where myoepithelial cells and 
basal cells of the epithelium are present.  Nonhomoge-
neous expression of intermediate ﬁ laments in AdCC has 
also been shown immunohistochemically.  Cytokeratin 
was more striking in luminal cells（type B）of the tu-
mor than in peripheral cells, indicating an inverse cor-
relation between cytokeratin and vimentin expression 
in AdCC27，30，32.  This observation also suggests a gradu-
al transition from basal to luminal cells, equivalent to 
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the differentiation seen in normal stratiﬁ ed epithelium.
　AdCC cells can also be divided into three subgroups 
histologically : cribriform, tubular, and solid（Fig. 1）. 
The most characteristic pattern is cribriform, created by 
many pseudocysts scattered in cell islands（Fig. 1C）. 
Perzin et al.29 reported that patients whose tumors con-
sisted of the tubular or cribriform pattern had a favor-
able outcome, in contrast to patients with solid type. 
Several reports have indicated that the cribriform pat-
tern is associated with the longest patient survival 
time, followed by tubular and solid types1，21，22.  Howev-
er, other studies were unable to ﬁ nd a relationship be-
tween histological pattern and survival, since individual 
tumors often contained all three cell types33.  Perineural 
invasion may be more associated with an unfavorable 
outcome（Fig. 1D）.
　ECM-containing BM components are a histological 
feature of AdCC.  They are observed in the cribriform 
and tubular patterns of the pseudocyst lining and on 
the outer surface of cells comprising tubular areas.  BM 
consists of several types of macromolecules, including 
type IV collagen, laminin, ﬁ bronectin, heparin sulfate 
proteoglycan, and entactin.  These proteins have been 
demonstrated in the ECM surrounding AdCCs, in the 
pseudocystic spaces, hyaline stroma, and around tumor 
nests34.  Tumor cells appear to proliferate in contact 
with the BM and to inﬁ ltrate through BM-rich tissues
（Fig. 2）, such as peripheral nerves, blood vessels, and 
skeletal muscle35.  It has been clearly demonstrated 
that BM molecules in the stroma are produced by the 
tumor cells themselves32（see sect. 4）.  Furthermore, 
the biosynthetic and metabolic changes that occur in 
the ECM might be involved in malignant transforma-
tion.
　Many histochemical- and morphological-based obser-
vations suggest that myoepithelial-like cells are respon-
sible for the production of ECM components, including 
BM molecules32.  We previously found a correlation be-
tween an increase in glycosaminoglycan synthesis and 
the expression of a myoepithelial-like phenotype in cul-
tured cells36.  The production of ECM and BM by AdCC 
cells is exclusively a myoepithelial or basal cell charac-
teristic, and is vigorous, but disorganized, compared 
with production in normal tissue.
4. Biological characteristics of cultured cells
1）ECM production and degradation by AdCC-de-
rived cell lines in vitro are regulated by the uPA-
plasmin system.
　Well-characterized cell lines established from human 
AdCCs, such as Acc-2, Acc-337, and Acc-M38（established 
at Shanghai Second Medical University）, and ACCS9，39, 
ACCY32, and ACCT,  serve as useful tools for under-
standing the biology of this type of tumor.  AdCCs vigor-
ously produce and accumulate ECM, including base-
ment membrane components.  As it does in vivo, the 
ACCY, ACCS, Acc-2, and Acc-3 cell lines have been 
shown to produce large amounts of ECM, including col-
lagen, elastin, basal lamina components, and mucopoly-
saccharides1，32，34，40.  The amount of ECM produced by 
ACCS cells is comparable to that produced by normal 
mesenchymal cells.  ACCS and ACCY cells are of the 
basal-myoepithelial cell type（see Sect. 2, type A cells）
and form pseudocysts in vitro.  This ﬁ nding supports 
suggestions that myoepithelial-like cells are responsible 
for ECM production, including basal lamina macromole-
cules, and that the accumulation of ECM in intercellu-
lar spaces contributes to the formation of the stroma 
surrounding AdCCs32.
　In addition to extensive ECM-producing activity, 
ACCS cells can degrade considerable amounts of ECM 
elaborated by mesenchymal cells, mainly via the uPA-
plasmin system9.  ACCS cells produce high levels of sev-
eral proteolytic enzymes, including uPA, MMP-2, and 
MMP-9 and ECM degradation by the cells is both plas-
minogen-dependent and closely associated with uPA ex-
pression9.  In vitro study has demonstrated that ECM 
produced by ACCS cells contains PAI-1（Fig. 1E）and 
is consequently resistant to degradation9.  As a result, 
ECM components can accumulate in the intercellular 
spaces, thereby forming a pseudocyst（Fig. 1C and Fig. 
2）, which is the characteristic architecture of AdCC32. 
Since, in this way, AdCC cells are surrounded by their 
own ECM, as well as by normal host connective tissue, 
they are able to proliferate along the tumor-produced 
ECM and then bind to and ﬁ nally invade adjacent nor-
mal tissues（Fig. 2）.
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2）EGF induces activation of AP-1, which simu-
lates ECM-degrading protease production and 
migration, while dexamethasone inhibits these 
events
　Certain growth factors, such as epidermal growth fac-
tor（EGF）, regulate tumor invasiveness by altering cell 
adhesion, ECM-degrading protease production, and mo-
tility41，42.  Treatment of AdCC cells and oral squamous 
cell carcinoma（SCC）cells with EGF stimulates sever-
al activities, such as ECM degradation, migration, and 
Matrigel（artiﬁ cial basement membrane protein）inva-
sion9，43，44.  In various types of cells, including AdCC and 
SCC cells, EGF induces increased expression of uPA 
and uPAR proteins and mRNA through activation of 
transcription factor activator protein-1（AP-1）44.  Both 
EGF-induced invasion and uPA and uPAR expression 
are markedly inhibited by dexamethasone（DEX）
through a reduction of DNA-AP-1 binding and the in-
duction of PAI-1 expression44.  Rosenthal et al.42 report-
ed that EGF also stimulates the production of MMP-1, 
stromelysin-1, and MMP-9 in a process that may be 
mediated by AP-1.  MMPs, particularly MMP-2 and 
MMP-9, are important for the degradation and invasion 
of BM and ECM45，46.  Initially, MMPs released from 
cells are inactive ; they are converted to active forms by 
other MMPs or plasmin47，48.  Since uPA is activated by 
binding with uPAR, the uPA-uPAR interaction is essen-
tial for augmenting proteolytic activity and uPAR-medi-
ated signaling, which ultimately induce motility and in-
vasion.  DEX inhibits the expression of both uPA and 
uPAR by blocking AP-1 activation, and therefore may be 
useful in the treatment of malignant tumors44.
3）AdCC migrates to types I and IV collagens
　As noted above, due to its proclivity for invading 
nerve and endothelial sheaths1，49, the frequency of re-
currence and distant metastasis of AdCC is very high. 
Data from our laboratory suggest that AdCC cells ini-
tially proliferate along tumor-produced ECM, contain-
ing BM components, and that these invasive cells ad-
here and migrate to nerve and endothelial sheaths, 
which also contain BM components（Fig. 2）.  In fact, 
ACCS-produced ECM strongly stimulates the migration 
of these cells in vitro50.  Moreover, the ability of ACCS 
and ACCT cells to migrate and adhere to ECM, espe-
cially types I and IV collagen, is greater than that of 
oral SCC cell lines（Fig. 3）39，51, although AdCC and 
SCC cells have very similar proﬁ les of integrin subunit 
expression51.  The collagen-stimulated migration of AdCC 
cells is largely and exclusively inhibited by anti-α2 inte-
grin antibodies, suggesting that α2 integrin is function-
ally important for the adhesion and migration of AdCC 
cells to collagen.
4）AdCC cell migration to collagens may be due 
to uPAR overexpression, which plays a key role in 
focal-adhesion assembly and migration
　Various integrin-associated proteins have been re-
ported to modulate integrin signaling and to control 
integrin-mediated events.  The multifunctional surface 
receptor uPAR is one such protein that controls signal-
ing, adhesion, and migration52.  Compared with normal 
cells, malignant tumor cells usually express higher lev-
els of uPA and uPAR5，53，54, which results in increased 
tumor cell invasion in vitro44.  The results of our studies 
showed that AdCC cells produce a large amount of uPA 
and degrade ECM via the uPA-plasmin system9, and 
that uPAR surface protein and mRNA expression are 
greater in AdCC than in SCC cell lines39.  Combined, 
these ﬁ ndings suggest that the characteristic properties 
of AdCC cells, invasion and metastasis, are mainly reg-
ulated by the uPA-uPAR system.  In this respect, uPAR 
has been shown to facilitate cell-surface plasminogen 
activation, which generates a proteolytic cascade con-
tributing to matrix degradation during tumor invasion, 
and might function in cell adhesion and migration9，44. 
Several studies have demonstrated the presence of 
uPAR at focal adhesion sites and at leading edges of mi-
grating cells, suggesting that uPAR physically associ-
ates with integrins55-57.  Figure 4B shows a cell clone 
transfected with pECF-N1 vector containing uPAR 
cDNA and cDNA for the enhanced cyan ﬂ uorescent vari-
ant of green ﬂ uorescent protein（CFP）.  CFP-uPAR 
overexpression resulted in an increased frequency of the 
formation of lamellipodia, in which CFP-uPAR was con-
centrated58.  This ﬁ nding indicates that receptor expres-
sion plays a role in actin reorganization, which is regu-
lated by genes of the Rho family.  When AdCC cells were 
plated on collagen, the surface level of uPAR increased, 
and numerous focal adhesions, consisting of uPAR, vin-
culin, and paxillin, were assembled（Fig. 4A, C and D）, 
whereas collagen-stimulated SCC cells or AdCC cells 
plated on other types of ECM, such as ﬁ bronectin, failed 
to assemble focal adhesions39.  Figure 4C shows a case 
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of comparison of a transfectant of ACCS with uPAR an-
tisences（ACCS-AS）and control clone（ACCS-zeo）. 
The surface uPAR level of AdCC cells was up-regulated 
by collagen stimulation in the absence of uPAR mRNA 
induction39.  As shown in experiments with EGF, uPAR 
expression is controlled mainly at the transcriptional 
level44.  Post-transcriptional regulation and recycling of 
uPAR to the plasma membrane represent additional 
levels of regulation7.  In a study applying immunocyto-
chemical staining, we demonstrated the translocation of 
uPAR from the cytoplasm to focal adhesions on collagen 
stimulation of AdCC cells, while SCC cells expressing 
low levels of uPAR were less able to assemble focal 
adhesions.  In AdCC cells, uPAR co-localized with α2β1 
integrin, paxillin, and vinculin at focal adhesions 
following collagen（Fig. 4C and D）, but not ﬁ bronectin, 
stimulation39.  These ﬁ ndings suggest that on collagen 
activation, uPAR migrates to the focal adhesion via its 
interaction with a collagen receptor, probably the α2 in-
tegrin receptor.  Recent reports indicated that uPAR, 
which is a GPI-anchored protein, plays an important 
role in regulating cell migration via the modiﬁ cation of 
actin-integrin adhesive complexes6，55，57，59，60.
　The down-regulation of uPAR inhibits the growth and 
migration of carcinoma cells in vitro61，62, alters cytoskel-
etal organization in human glioma cells63 and ﬁ bro-
blasts64, and inhibits colon cancer metastasis in a nude 
mouse model65.  However, how down-regulation of uPAR 
Fig. 1 Adenoid cystic carcinoma（AdCC）is composed of distinct populations of cells that can be arranged in three main pat-
terns : solid（A）, tubular（B）, and cribriform（C）. The most characteristic pattern, cribriform, is created by many pseu-
docysts containing extracellular matrix（ECM）produced by AdCC cells. Perineural inﬁ ltration is also a characteristic 
feature of this tumor（D）. E, Analysis of radio-labeled ECM of cultured AdCC cells and ﬁ broblasts by SDS-PAGE and 
autoradiography. Whole and IP（PAI-1）indicate whole ECM and immunoprecipitation of the ECM with anti-PAI-1 an-
tibody, respectively. The intensity of PAI-1 band（MW 45 kDa）in AdCC ECM（lane 2）is greater than that of ﬁ broblast 
ECM（lane 4）. 
Fig. 2 Invasion by adenoid cystic carcinoma（AdCC）cells is regulated mainly by urokinase-type plasminogen activator（uPA）
and uPA receptor（uPAR）. AdCC cells initially grow as a solid mass ［1］ and produce a large amount of extracellular ma-
trix（ECM）, which accumulates in the intercellular space, resulting in the formation of a cribriform pattern, created by 
many pseudocysts. Since patients with the cribriform pattern have a favorable outcome, pseudocyst forming cells might 
be less invasive. After the loss of intercellular junctions, for example through reduced expression or cleavage of cadher-
ins, invasive tumor cells detach ［2］ and then migrate preferentially into tumor-produced or mesenchymal produced-EC-
Ms, collagens ［3］, via interaction of integrin, protease（uPA）and protease-receptor（uPAR）. The high afﬁ nity of inva-
sive cells for type IV collagen allows their further migration into nerve sheaths, resulting in paralysis of the facial nerve 
and pain, and into vascular endothelial sheaths ［4］, resulting in distant metastasis. After AdCC cells intravasate into 
the bloodstream ［5］, the tumor cells, which have platelet aggregation activity ［6］, adhere to vascular endothelial cells of 
distant organs and extravasate into those tissues. Subsequently, the tumor cells settle in the parenchyma of target or-
gans（especially the lung）, where they create metastatic deposits ［7］.
Fig. 3 Comparison of migratory response of different cells to ECM proteins. Two AdCC cell lines（ACCS and ACCT）and two 
SCC cell lines（NA and SCCTF）were used for the haptotaxis assay using modiﬁ ed Boyden chambers. Brieﬂ y, polycar-
bonate ﬁ lters were pre-coated with 10 μg/ml of the indicated ECM on the side facing the lower wells. Cells（1× 105）
were seeded in the upper compartments and migratory cells on the bottom of the ﬁ lter were counted. The relative migra-
tions of AdCC cell lines to type I and IV collagens are 10- and 5-fold those of the SCC cell lines NA and SCCTF, respec-
tively. Further blocking experiments with speciﬁ c antibodies showed that the enhanced migration of AdCC cells to the 
collagens was signiﬁ cantly and exclusively inhibited by anti-α2 integrin antibody（not shown）.
Fig. 4 uPAR interactions with uPA, integrin, and ECM in AdCC cell invasion. A, uPAR is a glycosyl phosphatidylinositol（GPI）
-anchored protein consisting of three homologous domains : D1, D2, and D3. D1 binds various proteins, such as uPA, 
PAI-1, and vitronectin, a type of ECM. uPA bound to uPAR exhibits enhanced proteolytic activity and directly activates 
plasminogen and matrix metalloproteases, which results in enhanced ECM degradation. The uPA-uPAR interaction also 
mediates several signaling events, regulates cell adhesion on the ECM, modulates integrin activity, and triggers cell mi-
gration. AdCC cells overexpress uPAR, which co-localizes with integrin, paxillin and vinculin on focal adhesions follow-
ing collagen stimulation. B, CFP-uPAR overexpression leads to increased formation of lamellipodia, in which CFP-uPAR 
is concentrated（white arrowhead）. C, Immunoprecipitation study demonstrates the effect of uPAR down-regulation on 
the association of focal adhesion components. ACCS-AS cells, transfected with the vector expressing uPAR antisense 
RNA, and control cloned ACCS-zeo cells, transfected with empty vector that expressed an amount of uPAR protein and 
mRNA comparable to that of parental ACCS, were plated on ﬁ bronectin（FN）or collagen I（COLL I）. The cell protein 
complexes were immunoprecipitated using anti-paxillin antibody and then examined by Western blotting with antibody 
to uPAR. Novel interaction between paxillin and uPAR is found in AdCC-zeo cells induced by type I collagen stimulation. 
D, Immunocytochemical staining shows the colocalization of uPAR with vinculin on type IV collagen.
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inhibits invasion and metastasis is poorly understood. 
Our immunoprecipitation experiments showed novel in-
teractions between α2β1 integrin or paxillin and uPAR 
in AdCC cells induced by type I collagen stimulation. 
Therefore, in order to elucidate the association of uPAR 
with collagen-induced events, we established an ACCS-
AS cell line transfected with a vector expressing anti-
sense uPAR RNA.  uPAR expression in these cells is 
about 10% that of parental ACCS cells at both the pro-
tein and mRNA levels.  Collagen-stimulated migration 
and focal adhesion assembly of α2 integrin, vinculin, 
and paxillin were strongly reduced in ACCS-AS cells. 
Furthermore, down-regulation of uPAR led to conforma-
tional changes in focal adhesions and actin organization
（reduced stress ﬁ bers）.  The expression and distribu-
tion of α2 integrin were obscured in ACCS-AS cells plat-
ed on any ECM, and there were fewer focal adhesions, 
as shown by the staining pattern for paxillin.  This sug-
gests that uPAR plays a role in regulating the recruit-
ment of α2 integrin to focal adhesions, and in their as-
sembly, and that migration of AdCC cells to types I and 
IV collagens is due to the overexpression of uPAR.
5）Acc-M is a model cell line for examining the 
mechanism of lung metastasis
　In contrast to oral SCCs, which metastasize lymphati-
cally, AdCCs undergo blood-borne metastasis and in 
most cases metastasize to the lungs.  Although the un-
derlying molecular mechanisms are complex, it is clear 
that metastasis requires a cascade of sequential steps 
involving the coordination of adhesion, motility, and 
growth66.  After tumor cells intravasate into the blood-
stream, they evade innate immune surveillance, adhere 
to vascular endothelial cells of distant organs, and ex-
travasate into those tissues.  Subsequently, the malig-
nant cells settle in the parenchyma of target organs 
where they create metastatic deposits67.
　The well-characterized lung metastatic AdCC cell line 
Acc-M was established by repeated isolation from lung 
metastatic foci of Acc-2 cells38.  Cloning of the cells re-
vealed a close relationship between metastasis and 
platelet aggregation activity（Fig. 2）.  Acc-M-GFP ex-
presses green ﬂ uorescence protein（GFP）and is useful 
for the visualization of metastatic foci in vivo.  Injection 
of Acc-M-GFP cells into the tail vein of athymic nude 
mice resulted in metastasis to multiple sites, including 
lung, muscle, bladder, and bone68.  This experiment at-
tempted to model the events that occur after tumor cells 
intravasate into the bloodstream.  We showed that the 
adhesion of Acc-M cells to human umbilical vein endo-
thelial cells is greater than that of non-metastatic AdCC 
cells, and that the interaction between tumor cells and 
vascular endothelial cells is mediated through adhesion 
molecules, including E- and P-selectins69.  These are ex-
pressed on stimulated endothelial cells and activated 
platelets and react with selectin glycoprotein ligand, 
which mediates leukocyte rolling on stimulated endo-
thelial cells and the heterotypic aggregation of activated 
platelets on leukocytes.  A recent study suggested that 
P-selectin binds to cancer cells, including Acc-M, in vitro 
and promotes the growth and metastasis of human car-
cinomas in vivo and sulfation was also shown to be es-
sential for Acc-M cell adhesion to P-selectin70.
　Although the molecular mechanisms of AdCC cells 
are complex, it seems likely that metastasis is regulated 
by interactions of adhesion molecules and proteases. 
Further studies are required to resolve the complex 
mechanisms. 
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